| Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies M Egger, M May, G Chêne, AN Phillips, B Ledergerber, F Dabis, ... The Lancet 360 (9327), 119-129, 2002 | 2104 | 2002 |
| Combination antiretroviral therapy and the risk of myocardial infarction Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group New England Journal of Medicine 349 (21), 1993-2003, 2003 | 2103 | 2003 |
| Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies Antiretroviral Therapy Cohort Collaboration The Lancet 372 (9635), 293-299, 2008 | 2004 | 2008 |
| Changing patterns of mortality across Europe in patients infected with HIV-1 A Mocroft, S Vella, TL Benfield, A Chiesi, V Miller, P Gargalianos, ... The Lancet 352 (9142), 1725-1730, 1998 | 1663 | 1998 |
| Decline in the AIDS and death rates in the EuroSIDA study: an observational study A Mocroft, B Ledergerber, C Katlama, O Kirk, P Reiss, AA Monforte, ... The Lancet 362 (9377), 22-29, 2003 | 1635 | 2003 |
| Liver-related deaths in persons infected with the human immunodeficiency virus: the D: A: D study Data Collection on Adverse Events of Anti-HIV Drugs Study Group Archives of internal medicine 166 (15), 1632-1641, 2006 | 1488 | 2006 |
| Cardiovascular disease risk factors in HIV patients–association with antiretroviral therapy. Results from the DAD study N Friis-Møller, R Weber, P Reiss, R Thiébaut, O Kirk, AA Monforte, ... Aids 17 (8), 1179-1193, 2003 | 1388 | 2003 |
| Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D: A: D study: a multi-cohort collaboration D: A: D Study Group The Lancet 371 (9622), 1417-1426, 2008 | 1159 | 2008 |
| Trends in underlying causes of death in people with HIV from 1999 to 2011 (D: A: D): a multicohort collaboration CJ Smith, L Ryom, R Weber, P Morlat, C Pradier, P Reiss, JD Kowalska, ... The Lancet 384 (9939), 241-248, 2014 | 1113 | 2014 |
| Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies A Trickey, MT May, JJ Vehreschild, N Obel, MJ Gill, HM Crane, ... The lancet HIV 4 (8), e349-e356, 2017 | 1091 | 2017 |
| Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse … SW Worm, C Sabin, R Weber, P Reiss, W El-Sadr, F Dabis, S De Wit, ... The Journal of infectious diseases 201 (3), 318-330, 2010 | 826 | 2010 |
| Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients AA Monforte, AC Lepri, G Rezza, P Pezzotti, A Antinori, AN Phillips, ... Aids 14 (5), 499-507, 2000 | 761 | 2000 |
| Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection A Ammassari, R Murri, P Pezzotti, MP Trotta, L Ravasio, P De Longis, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 28 (5), 445-449, 2001 | 677 | 2001 |
| Correlates and predictors of adherence to highly active antiretroviral therapy: overview of published literature A Ammassari, MP Trotta, R Murri, F Castelli, P Narciso, P Noto, J Vecchiet, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 31, S123-S127, 2002 | 666 | 2002 |
| Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D: A: D) study S De Wit, CA Sabin, R Weber, SW Worm, P Reiss, C Cazanave, ... Diabetes care 31 (6), 1224-1229, 2008 | 609 | 2008 |
| Late diagnosis of HIV infection: epidemiological features, consequences and strategies to encourage earlier testing E Girardi, CA Sabin, AA Monforte JAIDS Journal of Acquired Immune Deficiency Syndromes 46, S3-S8, 2007 | 455 | 2007 |
| Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study N Friis-Møller, R Thiebaut, P Reiss, R Weber, A D'Arminio Monforte, ... European journal of cardiovascular prevention & rehabilitation 17 (5), 491-501, 2010 | 437 | 2010 |
| Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? E Fontas, F Van Leth, CA Sabin, N Friis-Møller, M Rickenbach, ... The Journal of infectious diseases 189 (6), 1056-1074, 2004 | 428 | 2004 |
| Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study A Mocroft, R Brettle, O Kirk, A Blaxhult, JM Parkin, F Antunes, P Francioli, ... Aids 16 (12), 1663-1671, 2002 | 414 | 2002 |
| Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2 … P Cahn, JS Madero, JR Arribas, A Antinori, R Ortiz, AE Clarke, CC Hung, ... The Lancet 393 (10167), 143-155, 2019 | 397 | 2019 |
